The HOMAGE randomised trial found that spironolactone reduced left atrial volume index (LAVI), E:A ratio, and a marker of collagen type I synthesis (PICP) in patients at risk of heart failure (HF). Previous trials showed that patients with HF, preserved ejection fraction and low serum collagen type I C-terminal telopeptide to matrix metalloproteinase-1 (CITP:MMP-1) ratio, associated with high collagen

Remote monitoring of pulmonary artery (PA) pressure has reduced heart failure (HF) hospitalizations in chronic HF as elevation of PA pressure provides information that can guide treatment. The venous system is characterized by high capacitance, thus substantial increases in intravascular volume can occur before filling pressures increase. The inferior vena cava (IVC) is a highly compliant venous conduit

Radoslaw Sierpinski, Krystian Josiak, Tomasz Suchocki, KatarzynaWojtas-Polc, Grzegorz Mazur, Aleksandra Butrym, Piotr Rozentryt, Peter van der Meer, Josep Comin-Colet, Stephan von Haehling, Wojciech Kosmala, Monika Przewlocka-Kosmala, Waldemar Banasiak, Jolanta Nowak, Adriaan A. Voors, Stefan D. Anker, John G.F. Cleland, Piotr Ponikowski, and Ewa A. Jankowska. The affilaition of the author Stephan

Whereas the combination of anaemia and chronic kidney disease (CKD) has been extensively studied in patients with heart failure (HF), the contribution of iron deficiency (ID) to this dysfunctional interplay is unknown; we aimed to assess clinical associates and pathophysiological pathways related to ID in this multimorbid syndrome.

To evaluate the performance of the WATCH-DM risk score, a clinical risk score for heart failure (HF), in patients with dysglycaemia and in combination with natriuretic peptides (NPs).

Patients with obesity frequently present with dyspnoea. Biomarkers that reflect wall stress are often used to evaluate circulatory congestion and help determine whether dyspnoea is of cardiac causes. Patients with obesity display greater external restraint on the heart, which may alter relationships between intravascular pressures and stress markers.

Outpatient treatment for the worsening of signs and symptoms of heart failure (HF) is usually not incorporated in the main outcomes of HF trials. Patients with HF and a preserved ejection fraction (HFpEF) may experience frequent episodes of outpatient worsening HF. The aim of this study was to evaluate the frequency, prognostic impact, and the effect of spironolactone on outpatient diuretic intensification

In patients with current or a history of hyperkalaemia, treatment with renin–angiotensin–aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K+) binder, may improve serum K+ levels and adherence to RAASi.

Insufficient diuretic response frequently occurs in patients admitted for acute heart failure (HF) and is associated with worse clinical outcomes. Recent studies have shown that measuring natriuresis early after hospital admission could reliably identify patients with a poor diuretic response during hospitalization who might require enhanced diuretic treatment. This study will test the hypothesis that

For patients with acute heart failure (AHF), substantial diuresis after administration of loop diuretics is generally associated with better clinical outcomes but may cause creatinine to rise, suggesting renal function decline. We investigated the interaction between diuretic response and worsening renal function (WRF) on clinical outcomes in patients with AHF.

Guideline-directed medical therapy (GDMT) has the potential to reduce the risks of mortality and hospitalisation in patients with heart failure (HF) with reduced ejection fraction (HFrEF). However, real-world data indicate that many patients with HFrEF do not receive optimised GDMT, which involves several different medications, many of which require up-titration to target doses. There are many challenges

Despite aortic stenosis (AS) relief, patients undergoing transcatheter aortic valve implantation (TAVI) are at increased risk of developing heart failure (HF) within first months of intervention. Sodium–glucose co-transporter 2 (SGLT-2) inhibitors have been shown to reduce the risk of HF hospitalization in individuals with diabetes mellitus, reduced left ventricular ejection fraction and chronic kidney

To assess the feasibility and efficacy of interatrial shunt devices (IASD) for the treatment of chronic heart failure (CHF).

While the first part of the scientific statement on the pathophysiology of Takotsubo syndrome was focused on catecholamines and the sympathetic nervous system, in the second part we focus on the vascular pathophysiology including coronary and systemic vascular responses, the role of the central and peripheral nervous systems during the acute phase and abnormalities in the subacute phase, the gender

Circulating biomarkers and imaging techniques provide independent and complementary information to guide management of heart failure (HF). This consensus document by the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) presents current evidence-based indications relevant to integration of imaging techniques and biomarkers in HF. The document first focuses on application of

Large-scale trials have evaluated the effects of treatments on major renal outcomes, but the definition of a renal event has varied from trial to trial. In defining a renal event, trialists included patients who needed renal replacement therapy or whose estimated glomerular filtration rate (eGFR) declined to <10–15 mL/min/1.73 m2, and they also included patients who experienced large and sustained

Rebecca J. Woolley, Daan Ceelen, Wouter Ouwerkerk, Jasper Tromp, Sylwia M. Figarska, Stefan D. Anker, Kenneth Dickstein, Gerasimos Filippatos, Faiez Zannad, Metra Marco, Leong Ng, Nilesh Samani, Dirk J. van Veldhuisen, Chim Lang, Carolyn S. Lam and Adriaan A. Voors The first and last name of the 10th author, Marco Metra, was originally published in the wrong order and this has now been corrected in

This article refers to ‘Recovery of cardiac function following COVID-19 – ECHOVID-19: a prospective longitudinal cohort study’ by M.C.H. Lassen et al., published in this issue on pages xxx. There has been a large number of publications concerning cardiac complications in acute coronavirus disease 2019 (COVID-19) infection.1-5 Myocardial injury during the acute phase of COVID-19 raises the question

Hospitalization for acute heart failure (HF) is followed by a vulnerable time with increased risk of readmission or death, thus requiring particular attention after discharge. In this study, we examined the impact of intensive, early follow-up among patients at high readmission risk at discharge after treatment for acute HF.

Heart failure with reduced ejection fraction (HFrEF) and chronic obstructive pulmonary disease (COPD) individually cause significant morbidity and mortality. Their coexistence is associated with even worse outcomes, partly due to suboptimal heart failure therapy, especially underutilisation of beta-blockers. Our aim was to investigate outcomes in HFrEF patients with and without COPD, and the effects

Patients with heart failure (HF) who contract SARS-CoV-2 infection are at a higher risk of cardiovascular and non-cardiovascular morbidity and mortality. Regardless of therapeutic attempts in COVID-19, vaccination remains the most promising global approach at present for controlling this disease. There are several concerns and misconceptions regarding the clinical indications, optimal mode of delivery

Sympathetic overactivity, which predicts poor outcome in patients with heart failure, normalizes following cardiac transplantation. We tested the hypothesis that haemodynamic improvement following left ventricular assist device (LVAD) implantation is also associated with reductions in centrally generated sympathetic activity.

Wong YW, Mentz RJ, Felker G, Ezekowitz J, Pieper K, Heizer G, Hasselblad V, Metra M, O'Connor CM, Armstrong PW, Starling RC and Hernandez AF. In the original published version, the supporting information files were cited and listed incorrectly. This has now been corrected in the online version of the article https://onlinelibrary.wiley.com/doi/10.1002/ejhf.487. We apologize for this error.

To investigate the epidemiological and prognostic relationship between heart failure with preserved ejection fraction (HFpEF) and left-sided valve surgery using all-cause mortality as a primary endpoint.

In the past few decades, the treatment options for patients with advanced heart failure (HF) have changed dramatically.1 Since the introduction of (long-term) mechanical circulatory support (MCS), the prognosis and quality of life of these patients have improved significantly. Technological improvements have changed the landscape of left ventricular assist devices (LVADs): the first-generation pulsatile

This article refers to ‘Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients – a prospective cohort study’ by O. Itzhaki Ben Zadok et al., published in this issue on pages 1555–1559. Infectious diseases are a well-known major complication after solid organ transplantation. Heart transplant (HT) patients have a high mortality rate after severe acute respiratory syndrome coronavirus

We eagerly awaited the publication of an updated expert consensus on endomyocardial biopsy (EMB), which has been lacking for the past 14 years.1 In fact, notwithstanding the tremendous progresses made in the field of non-invasive cardiovascular imaging during this time window, EMB still provides fundamental diagnostic and prognostic information while also being an important research tool, and an updated

SARS-CoV-2 infection may lead to endothelial and vascular dysfunction. We investigated alterations of arterial stiffness, endothelial coronary and myocardial function markers 4 months after COVID-19 infection.